Pregnancy, Childbirth & Puerperium

Rh isoimmunization: prevention and management

Clinical Overview and When to Suspect Rh Isoimmunization

— First sensitizing event produces low-titer IgM (does not cross placenta) → memory B cells form.

— Subsequent exposure triggers anamnestic IgG response → IgG crosses placenta → fetal RBC hemolysis → hemolytic disease of the fetus and newborn (HDFN).

— Severity escalates with each successive RhD-positive pregnancy.

— RhD-negative pregnant patient carrying an RhD-positive (or unknown) fetus.

— Prior pregnancy without anti-D prophylaxis, prior transfusion of Rh-positive blood, IV drug use sharing needles, or solid-organ transplant from RhD+ donor.

— Delivery (vaginal or cesarean), spontaneous/induced abortion, ectopic pregnancy, molar pregnancy.

— Antepartum bleeding, abdominal trauma, external cephalic version, amniocentesis, CVS, cordocentesis.

— Any second- or third-trimester bleeding event regardless of severity.

— Positive indirect Coombs (antibody screen) at first prenatal visit in an RhD-negative patient.

— Prior infant with neonatal jaundice, exchange transfusion, hydrops, or unexplained fetal demise.

— Hydrops fetalis on ultrasound (skin edema, ascites, pleural/pericardial effusion, polyhydramnios).

Board pearl: Anti-Kell is increasingly tested—causes severe HDFN by suppressing fetal erythropoiesis, not just hemolysis, so MCA Dopplers remain the surveillance tool but amniotic bilirubin (ΔOD450) underestimates severity.

Definition: Rh isoimmunization (alloimmunization) occurs when an RhD-negative individual develops anti-D IgG antibodies after exposure to RhD-positive red blood cells, typically from a prior pregnancy, transfusion, or sensitizing event.

Pathophysiology in pregnancy:

Who is at risk:

Sensitizing events to recognize on Step 3:

When to suspect existing isoimmunization:

Why it still matters despite RhIg: Failures occur from missed dosing, unrecognized sensitizing events, inadequate dose for large fetomaternal hemorrhage (FMH), or non-D antigens (Kell, c, E).

Presentation Patterns and Key History

— Routine first-prenatal-visit labs reveal RhD-negative blood type with a positive antibody screen.

— Reflex testing identifies the antibody (anti-D, anti-c, anti-Kell, etc.) and titer.

— Obstetric history: gravidity/parity, prior miscarriages, ectopic, terminations, stillbirths, neonatal jaundice, exchange transfusions, NICU admissions, hydrops.

— Anti-D immunoglobulin (RhIg) history: Did the patient receive RhIg at 28 weeks and postpartum in prior pregnancies? Was RhIg given after any bleeding event, miscarriage, ectopic, amniocentesis, or trauma?

— Transfusion history: any prior RBC, platelet, or plasma transfusion; transplant history.

— Paternal blood type and zygosity if known—if father is RhD-negative, fetus is RhD-negative and surveillance is unnecessary; if RhD-positive heterozygous, fetal RhD genotyping is indicated.

— Vaginal bleeding at any gestational age.

— Abdominal trauma (MVC, fall, intimate partner violence).

— Recent invasive procedure (amniocentesis, CVS, ECV).

— Decreased fetal movement, especially in a previously sensitized patient.

— Maternal report of rapid uterine size increase (polyhydramnios).

— Decreased or absent fetal movement.

— Preterm contractions from uterine overdistension.

— Confirm access to a center capable of MCA Doppler and, if needed, intrauterine transfusion (IUT)—plan early referral if uninsured or rural.

Step 3 management: At the first prenatal visit, every patient gets ABO/RhD typing and antibody screen. If RhD-negative with negative screen → repeat screen at 28 weeks, then give 300 µg anti-D IgG. If RhD-negative with positive screen for anti-D → patient is already sensitized; RhIg is no longer beneficial, and management shifts to titer monitoring and MFM referral.

Asymptomatic screening discovery (most common Step 3 vignette):

History elements that must be elicited:

Current pregnancy red flags:

Symptoms suggesting fetal anemia/hydrops:

Social/access history (Step 3 flavor):

Physical Exam Findings (and Fetal Assessment when relevant)

— Fundal height greater than dates: suggests polyhydramnios from fetal hydrops or "mirror syndrome."

— Maternal edema, hypertension, proteinuria (Ballantyne/mirror syndrome): maternal preeclampsia-like state mirroring fetal hydrops—rare but life-threatening.

— Pallor or jaundice in the newborn at delivery; hepatosplenomegaly; petechiae; respiratory distress; generalized edema (hydrops).

— Middle cerebral artery peak systolic velocity (MCA-PSV) Doppler is the non-invasive standard for detecting fetal anemia.

— MCA-PSV >1.5 multiples of the median (MoM) for gestational age → moderate-to-severe fetal anemia, sensitivity ~100%.

— Begin Doppler surveillance at 18 weeks once titer threshold is crossed (typically ≥1:16 for anti-D; any detectable titer for anti-Kell).

— Repeat every 1–2 weeks depending on trajectory.

— Skin edema >5 mm, scalp edema ("halo sign").

— Ascites, pleural effusion, pericardial effusion.

— Polyhydramnios, placentomegaly (>4 cm thickness).

— Cardiomegaly with tricuspid regurgitation on fetal echo.

— Cord blood for type, direct Coombs, hemoglobin, bilirubin, reticulocyte count.

— Watch for "icterus gravis" (severe jaundice in first 24 h) and kernicterus risk.

Key distinction: MCA Doppler replaced amniotic ΔOD450 (Liley/Queenan curves) as the first-line non-invasive test. Reserve amniocentesis for cases where Doppler is equivocal or unavailable. Fetal blood sampling (cordocentesis) is now diagnostic and therapeutic—only performed when transfusion is immediately ready.

Maternal exam is usually unrevealing—isoimmunization is a serologic and ultrasound diagnosis, not a physical exam diagnosis.

Findings that may appear on exam:

Fetal hemodynamic assessment — the cornerstone:

Ultrasound signs of established hydrops (late finding—anemia is already severe):

Neonatal exam at delivery (if HDFN suspected):

Diagnostic Workup — Initial Labs and Screening

— ABO and RhD type on every pregnant patient.

— Indirect antibody screen (indirect Coombs) to detect maternal IgG against RBC antigens.

— If RhD-negative and antibody screen is negative → patient is a candidate for routine RhIg prophylaxis.

— If antibody screen is positive → identify the antibody (anti-D, anti-c, anti-C, anti-E, anti-Kell, anti-Duffy, etc.) and obtain a titer.

— Critical titer = 1:16 in most US labs—threshold at which severe fetal anemia becomes possible.

— Below critical titer: repeat titer monthly until 24 weeks, then every 2 weeks.

— At or above critical titer: titers no longer guide management—MCA Doppler surveillance begins.

— Paternal RhD typing and zygosity if paternity is certain. RhD-negative father → fetus is RhD-negative → no further workup.

— Heterozygous father or uncertain paternity → cell-free fetal DNA (cffDNA) from maternal plasma can determine fetal RhD status non-invasively, as early as 10–12 weeks.

— If cffDNA unavailable → amniocentesis for fetal RhD PCR (rarely needed now).

— All RhD-negative unsensitized patients get a repeat antibody screen at 28 weeks before administering 300 µg anti-D IgG, to confirm they have not already become sensitized.

— Neonatal cord blood type and direct Coombs.

— Kleihauer-Betke or flow cytometry on maternal blood after significant bleeding/trauma to quantify fetomaternal hemorrhage and calculate additional RhIg dosing.

Board pearl: A "weak D" (formerly Du) maternal type is generally treated as RhD-positive—no RhIg needed. Newer genotyping distinguishes partial D variants that DO require prophylaxis; when uncertain on the exam, default to giving RhIg.

First prenatal visit (universal):

Interpreting titers (anti-D specifically):

Anti-Kell exception: Any detectable anti-Kell titer is "critical" because severity correlates poorly with titer and disease can be devastating—go straight to MCA Doppler.

Determining fetal antigen status:

28-week repeat screen:

Postpartum/post-event labs:

Diagnostic Workup — Advanced and Fetal Studies

— Begin at 18 weeks once a critical titer is reached or anti-Kell is detected.

— Measure peak systolic velocity in the MCA; compare to gestational-age-specific MoM tables.

— >1.5 MoM = predicts moderate-to-severe anemia → proceed to fetal blood sampling and likely intrauterine transfusion.

— Repeat every 1–2 weeks; trend matters as much as absolute value.

— Surveillance continues until ~35 weeks, after which Doppler accuracy declines.

— Non-invasive, performed on maternal plasma.

— Sensitivity >99% after 20 weeks; can be done as early as 10 weeks.

— Spares unnecessary surveillance when fetus is RhD-negative.

— Largely supplanted by MCA Doppler but still used in select centers.

— Measures bilirubin in amniotic fluid as a proxy for hemolysis.

— Limitation: unreliable for anti-Kell (suppresses erythropoiesis without proportional hemolysis).

— Direct measurement of fetal hematocrit, hemoglobin, blood type, direct Coombs, bilirubin.

— Performed only when intrauterine transfusion is prepared and ready—risk of fetal loss is ~1–2% per procedure.

— Indicated when MCA-PSV >1.5 MoM or hydrops is present.

— Assess cardiac function, tricuspid regurgitation, and signs of high-output failure in suspected severe anemia or hydrops.

— Neonatal direct Coombs, hemoglobin, reticulocyte count, peripheral smear (spherocytes/nucleated RBCs), serial bilirubin.

Step 3 management: When MCA-PSV first exceeds 1.5 MoM at <35 weeks, refer/transfer to a maternal-fetal medicine center capable of IUT—do not delay. After 35 weeks, the balance shifts toward delivery rather than IUT because procedural risk exceeds neonatal management risk.

MCA-PSV Doppler — the central surveillance tool:

Cell-free fetal DNA for RhD genotyping:

Amniocentesis (ΔOD450 / Liley or Queenan curves):

Percutaneous umbilical blood sampling (PUBS, cordocentesis):

Fetal echocardiography:

Postnatal confirmation:

Risk Stratification and Management Pathway

— Branch 1: Is the mother RhD-negative? (Type & screen)

— Branch 2: Is she already sensitized? (Antibody screen result)

— Branch 3: Is the fetus actually antigen-positive? (Paternal type, cffDNA)

— Routine antepartum RhIg 300 µg at 28 weeks.

— Additional RhIg for any sensitizing event (bleeding, trauma, procedure, ECV).

— Postpartum RhIg within 72 hours if neonate is RhD-positive.

— Kleihauer-Betke after delivery or significant trauma to detect large FMH requiring extra dosing.

— Monthly titers until 24 weeks, then every 2 weeks.

— Determine fetal antigen status (cffDNA or paternal typing).

— If titer rises to critical or fetus is antigen-positive → escalate to Pathway C.

— Fetal antigen status confirmed positive.

— MCA-PSV every 1–2 weeks starting at 18 weeks.

— Co-manage with MFM.

— If MCA-PSV >1.5 MoM: PUBS + IUT.

— Continue IUTs every 1–3 weeks as needed.

— Uncomplicated sensitized pregnancy without anemia: 37–38 weeks.

— Pregnancies requiring IUT: typically deliver at 35–37 weeks, after last IUT and steroid course.

— Hydrops or refractory anemia near term: deliver as soon as feasible after corticosteroids if <34 weeks.

Board pearl: The classic exam trap: a sensitized patient (positive antibody screen for anti-D) presents at 28 weeks. Do NOT give RhIg—it provides no benefit once sensitization has occurred and may confuse future serologic testing. Shift to titer/Doppler surveillance.

Three branch points define management:

Pathway A — RhD-negative, unsensitized (the prevention pathway):

Pathway B — Sensitized, low titer (below critical, anti-D <1:16):

Pathway C — Sensitized, critical titer or any anti-Kell:

Delivery timing:

Mode of delivery: Vaginal delivery preferred unless obstetric indications dictate cesarean; avoid invasive fetal monitoring if possible to reduce FMH.

Pharmacotherapy — Anti-D Immunoglobulin (RhIg) Regimen

— 300 µg (1500 IU) IM (or IV for some preparations) covers up to 30 mL of fetal whole blood or 15 mL of fetal RBCs.

— 50 µg "mini-dose" sufficient for first-trimester events (<12 weeks): spontaneous/induced abortion, ectopic, threatened abortion with bleeding.

— 28 weeks gestation: routine antepartum dose (after repeat antibody screen confirms negative).

— Within 72 hours of delivery of an RhD-positive (or unknown) neonate.

— Sensitizing events: spontaneous abortion, induced abortion, ectopic pregnancy, molar pregnancy, CVS, amniocentesis, cordocentesis, ECV, abdominal trauma, antepartum bleeding, fetal demise.

— Some guidelines now also recommend RhIg after first-trimester procedural abortions >10 weeks; practices vary.

— Perform Kleihauer-Betke or flow cytometry after high-risk events or delivery with risk factors (abruption, manual placental extraction, trauma, twins, cesarean).

— Formula: (% fetal cells × 50) / 30 = number of 300 µg vials, then round up and add one extra vial.

— Maximum efficacy when given within 72 hours, but still give up to 28 days if missed—partial protection remains.

— Local injection-site reactions, low-grade fever, rare hypersensitivity.

— IV preparations carry small risk of hemolysis in RhD-positive recipients (irrelevant here—patient is RhD-negative).

— Confirm RhIg administration in the medical record at every encounter; lapses are the most common cause of preventable sensitization.

CCS pearl: On a CCS-style case, order "Rh immune globulin, IM, 300 µg" with note "after antibody screen confirms RhD-negative, unsensitized." Re-dose postpartum after cord blood confirms neonate is RhD-positive.

Mechanism: Passive IgG anti-D binds fetal RhD-positive RBCs in the maternal circulation, promoting clearance before they trigger a maternal immune response. Prevents primary sensitization; does not treat existing sensitization.

Standard dosing (US):

Standard indications and timing:

Calculating additional doses for large FMH:

The 72-hour rule:

Adverse effects:

Patient counseling pearls:

Procedures — Intrauterine Transfusion and Delivery Logistics

— Indicated when MCA-PSV >1.5 MoM, hydrops fetalis, or fetal hematocrit <30% on PUBS, typically between 18 and 35 weeks.

— Performed by MFM specialist under continuous ultrasound guidance.

— Intravascular IUT (preferred): needle into umbilical vein at placental cord insertion; transfuse O-negative, CMV-negative, irradiated, leukoreduced, hematocrit ~75–85% packed RBCs cross-matched against maternal blood.

— Intraperitoneal IUT: reserved for very early gestation (<20 weeks) when vessels are inaccessible.

— Target post-transfusion hematocrit: 40–50%.

— Repeat every 1–3 weeks; intervals lengthen as transfused adult RBCs suppress fetal erythropoiesis.

— Fetal paralysis (vecuronium/atracurium) via cord to prevent fetal movement.

— Tocolysis if indicated; corticosteroids for lung maturity if ≥24 weeks and delivery possible.

— Procedure-related fetal loss: ~1–3% per IUT; cumulative risk increases with serial procedures.

— Last IUT generally by 35 weeks; deliver at 37–38 weeks if uncomplicated, earlier if disease severe.

— Antenatal corticosteroids if delivery anticipated <37 weeks (per recent late-preterm steroid recommendations).

— Deliver in a facility with NICU and neonatal exchange transfusion capability.

— Cord blood: type, direct Coombs, hemoglobin, bilirubin, reticulocytes.

— Initiate intensive phototherapy early; threshold lower than for routine jaundice.

— Exchange transfusion for rapidly rising bilirubin, severe anemia, or hydrops—uses O-negative blood cross-matched against mother.

— IVIG can reduce need for exchange transfusion in some cases.

— Monitor for late anemia for 6–12 weeks (suppression of erythropoiesis).

Step 3 management: When asked about neonatal treatment of HDFN, the order of operations is: phototherapy → IVIG → exchange transfusion, with transfusion using O-negative, CMV-negative, irradiated blood cross-matched to maternal serum (because anti-D persists in the neonate).

Intrauterine transfusion (IUT) — definitive fetal therapy:

Technique:

Periprocedural management:

Delivery planning:

Neonatal management at birth:

Special Populations — Renal/Hepatic Impairment and Older Gravidas

— RhIg is a passive immunoglobulin preparation; no dose adjustment is required for hepatic or renal dysfunction.

— Half-life is ~21–30 days regardless of organ function.

— Patients on hemodialysis can receive standard IM dosing; avoid IM injection sites near AV fistula.

— Rare but relevant: severe IgA deficiency carries risk of anaphylaxis to IgA in IgG preparations.

— Use IgA-depleted RhIg formulations or seek allergy/immunology consultation.

— Document allergic reactions clearly in chart and OB record.

— IM injection in a therapeutically anticoagulated patient (e.g., LMWH for VTE prophylaxis in pregnancy) risks hematoma.

— Options: hold LMWH 12–24 h before IM dose, or use IV anti-D preparation (e.g., WinRho).

— More likely to have had prior pregnancies, transfusions, or procedures—review entire transfusion and obstetric history.

— Higher background rate of comorbidities (HTN, diabetes) that compound preeclampsia/mirror-syndrome risk if hydrops develops.

— Antibodies against non-D antigens (Kell, Duffy, Kidd, c, E) more common in multiply-transfused patients (e.g., sickle cell disease).

— These antibodies are not prevented by RhIg—only anti-D is.

— Screening identifies them; management follows the same MCA-Doppler-based algorithm if titer is critical.

— Modern RhIg preparations are virally inactivated; transmission risk is essentially zero.

— Document informed consent including theoretical risk; do not withhold RhIg.

Board pearl: A sickle cell patient with prior transfusions who presents pregnant with a positive antibody screen frequently has non-D antibodies (anti-c, anti-E, anti-Kell). RhIg does nothing for these. Identification of the specific antibody dictates whether MCA Doppler surveillance is needed.

Hepatic and renal impairment:

IgA deficiency:

Patients on anticoagulation:

Older gravidas (advanced maternal age):

Patients with prior transfusion history:

Patients with hepatitis B or C, HIV:

Special Populations — Pregnancy Subgroups and Specific Scenarios

— <12 weeks: 50 µg mini-dose RhIg is adequate (small fetal RBC volume).

— ≥12 weeks: full 300 µg dose.

— Applies to spontaneous abortion, induced abortion (medical or surgical), ectopic pregnancy, molar pregnancy.

— Recent ACOG guidance suggests RhIg may be optional for very early (<12 weeks) spontaneous losses without instrumentation, but most US practices still administer it.

— Give RhIg to all RhD-negative unsensitized patients regardless of management (methotrexate, salpingostomy, salpingectomy).

— Theoretical question whether trophoblast expresses RhD; standard practice gives RhIg, especially for partial moles which contain fetal tissue.

— Larger placental mass → higher risk of significant FMH at delivery.

— Obtain Kleihauer-Betke postpartum to adjust dose upward.

— Give 300 µg RhIg afterward; FMH occurs in up to 5–10% of ECVs.

— Any trauma (MVC, fall, IPV) in RhD-negative patient → give RhIg, perform Kleihauer-Betke, continuous fetal monitoring for ≥4 hours (longer if contractions, abnormal tracing, or significant mechanism).

— Each bleeding episode warrants reassessment; some protocols re-dose every 12 weeks during ongoing bleeding.

— Confirm neonatal RhD type from cord blood before giving postpartum dose.

— If neonate is RhD-negative, postpartum RhIg is not needed.

— If RhIg was given at 28 weeks, the passive antibody may still be detectable in maternal serum at delivery (titers typically ≤1:4)—do not mistake for sensitization.

Key distinction: A maternal antibody screen positive for weak anti-D with low titer (≤1:4) at delivery in a patient who received antepartum RhIg almost always represents passive immunization, not sensitization. Still give postpartum RhIg if neonate is RhD-positive.

First-trimester pregnancy loss or termination:

Ectopic pregnancy:

Molar pregnancy:

Multiple gestation:

External cephalic version (ECV):

Abdominal trauma in pregnancy:

Antepartum bleeding (placenta previa, abruption, threatened preterm labor with bleeding):

Postpartum considerations:

Complications and Adverse Outcomes

— Fetal anemia: progressive, can become severe rapidly between surveillance visits.

— Hydrops fetalis: generalized edema, ascites, effusions; reflects fetal heart failure from severe anemia (Hb <7 g/dL typically).

— Intrauterine fetal demise: especially with untreated hydrops or missed surveillance.

— High-output cardiac failure: secondary to anemia-driven hyperdynamic circulation.

— Hyperbilirubinemia and kernicterus: unconjugated bilirubin crosses immature blood-brain barrier; deposits in basal ganglia → athetoid cerebral palsy, sensorineural hearing loss, gaze palsy, dental enamel dysplasia.

— Anemia at birth or "late anemia" at 4–6 weeks of life from continued hemolysis and erythropoietic suppression after IUT.

— Thrombocytopenia, hepatosplenomegaly, hypoglycemia (from islet cell hyperplasia in chronic intrauterine hemolysis).

— Persistent pulmonary hypertension in hydropic neonates.

— Ballantyne (mirror) syndrome: maternal preeclampsia-like syndrome mirroring fetal hydrops—HTN, proteinuria, edema, sometimes pulmonary edema. Resolves with delivery or fetal therapy.

— Procedural complications of IUT/PUBS: preterm labor, chorioamnionitis, bleeding, fetal bradycardia, emergency cesarean.

— Operative delivery rates are elevated.

— Children who received IUT generally have normal neurodevelopment in ~90%, though severe hydrops at first IUT confers higher risk of disability.

— Sensorineural hearing loss screening recommended through early childhood.

— Severity typically increases with each subsequent RhD-positive pregnancy.

— Plan all future pregnancies with MFM from the outset.

Board pearl: Kernicterus is the most feared preventable complication of HDFN. Aggressive phototherapy and timely exchange transfusion in the neonate, using the AAP bilirubin nomograms shifted to lower thresholds in isoimmunized infants, prevents permanent neurologic injury.

Fetal complications (the core morbidity):

Neonatal complications (HDFN spectrum):

Maternal complications:

Long-term neurodevelopmental outcomes:

Future pregnancies:

Escalation — ICU, Consultation, and Triage Decisions

— Any positive antibody screen with critical titer (anti-D ≥1:16) or any anti-Kell.

— Prior pregnancy affected by HDFN (recurrence rate is high and typically more severe).

— MCA-PSV >1.5 MoM.

— Hydrops fetalis on imaging.

— Need for IUT, cordocentesis, or amniocentesis for fetal antigen typing.

— Patients in rural or community settings should be transferred early—not at the moment of crisis—to a regional center with IUT capability, level III/IV NICU, and 24/7 MFM coverage.

— Coordinate transfer of records, prior titers, and prenatal imaging.

— Hydrops fetalis requiring imminent IUT or delivery.

— Mirror syndrome (mother) with worsening hypertension, pulmonary edema, or proteinuria.

— Active antepartum hemorrhage in a sensitized patient.

— Preterm labor in a pregnancy requiring continued IUT.

— Severe mirror syndrome with pulmonary edema, respiratory failure, or magnesium toxicity from preeclampsia management.

— Major obstetric hemorrhage at delivery (placenta previa/accreta in setting of multiple cesareans).

— Cord hemoglobin <10 g/dL or hydrops → immediate NICU admission, prepare for exchange transfusion.

— Bilirubin doubling rate >0.5 mg/dL/hour despite intensive phototherapy → exchange transfusion.

— Hemodynamic instability → consider pRBC transfusion, inotropes, mechanical ventilation.

— Neonatology (before delivery), pediatric hematology, blood bank (cross-matched units ready), anesthesia (cesarean possibility), genetic counseling for future planning.

CCS pearl: On a CCS case with rising MCA-PSV at 30 weeks in a regional hospital, the correct sequence is: MFM consult → transfer to tertiary center → admit → corticosteroids → PUBS with IUT readiness → plan delivery at 37 weeks. Do not attempt IUT outside a center that performs them routinely.

Maternal-fetal medicine (MFM) consultation triggers:

Transfer of care:

When to admit:

Maternal ICU/step-down considerations:

Neonatal escalation:

Consults to anticipate:

Key Differentials — Same Category (Causes of Fetal Anemia/Hydrops)

— Anti-Kell (K1): Second most common cause of severe HDFN in developed countries; mechanism includes erythroid suppression in fetal bone marrow, so anemia can be profound at relatively low titers. Any detectable titer warrants MCA Doppler.

— Anti-c (little c): Can cause severe HDFN; treat similarly to anti-D.

— Anti-C, anti-E, anti-e: Generally milder but can cause clinically significant disease.

— Anti-Duffy (Fya), anti-Kidd (Jka), anti-S, anti-s: Variable severity.

— ABO incompatibility: Common cause of mild neonatal jaundice (mother O, baby A or B), but rarely causes significant fetal anemia or hydrops—does not require antepartum surveillance.

— Anti-Lewis (Lea, Leb): IgM, does not cross placenta, no fetal effect.

— Anti-I, anti-P1: Also IgM, clinically insignificant in pregnancy.

— Parvovirus B19: Suppresses erythropoiesis; classic cause of non-immune hydrops with reticulocytopenia; check maternal IgM/IgG and consider PCR.

— Alpha-thalassemia major (Bart hemoglobin): Common in Southeast Asian populations; both parents alpha-thal carriers; fetal hydrops with severe microcytic anemia.

— Twin-twin transfusion syndrome: Recipient with hydrops in monochorionic twins.

— Fetal arrhythmia (SVT, complete heart block).

— Structural cardiac disease with high-output failure.

— Chromosomal abnormalities: Turner, Down syndrome can present with hydrops.

— Congenital infections (TORCH): CMV, toxoplasmosis, syphilis.

Key distinction: Hydrops + positive maternal antibody screen = immune hydrops (alloimmunization). Hydrops + negative antibody screen = non-immune hydrops → workup pivots to parvovirus PCR, fetal echo, karyotype/microarray, hemoglobin electrophoresis on parents, and TORCH studies.

Other red cell alloimmunization syndromes:

Antibodies that do NOT cause HDFN:

Non-immune hydrops fetalis (broad differential when antibody screen is negative):

Key Differentials — Other Categories (Neonatal Jaundice and Anemia)

— ABO incompatibility: Mother O, baby A or B; positive direct Coombs in ~30% of cases, microspherocytes on smear, usually milder, rarely requires exchange transfusion. Does not cause fetal anemia or hydrops.

— G6PD deficiency: X-linked; jaundice peaks day 2–3; bite cells and Heinz bodies; can be severe enough to cause kernicterus.

— Hereditary spherocytosis: Family history of jaundice, splenomegaly, gallstones; spherocytes on smear with negative Coombs (distinguishes from immune hemolysis).

— Pyruvate kinase deficiency: Autosomal recessive; non-spherocytic hemolytic anemia.

— Crigler-Najjar / Gilbert syndrome: Unconjugated hyperbilirubinemia without hemolysis; UGT1A1 deficiency.

— Breast milk jaundice: Onset day 4–7, peaks at 2 weeks, otherwise well infant.

— Cephalohematoma/extensive bruising: Resorbing blood load increases bilirubin.

— Fetomaternal hemorrhage (spontaneous or trauma-related).

— Twin-twin transfusion (donor twin).

— Hemorrhagic placental conditions.

— Cord accident, placental abruption, severe preeclampsia, congenital infection, lethal anomaly.

— Preeclampsia (without fetal hydrops).

— Acute fatty liver of pregnancy.

— HELLP syndrome.

— Idiopathic anasarca of pregnancy.

Board pearl: A neonate with jaundice, negative direct Coombs, and spherocytes on smear has hereditary spherocytosis until proven otherwise—not isoimmunization. A positive direct Coombs points back to immune-mediated hemolysis (ABO or Rh).

Causes of neonatal hyperbilirubinemia mimicking HDFN:

Causes of fetal anemia (non-immunologic) without hydrops:

Causes of fetal demise mimicking HDFN demise:

Maternal mimics of mirror syndrome:

Secondary Prevention and Long-Term Plan

— Document the specific antibody, peak titer, MCA-PSV trajectory, number and outcomes of IUTs in a permanent, portable record.

— Counsel that future pregnancies with antigen-positive fetuses will likely be earlier and more severely affected—plan from preconception.

— Discuss paternal testing and donor sperm options if the partner is homozygous antigen-positive and prior outcomes were catastrophic.

— Refer for preimplantation genetic testing (PGT) with IVF as an option to select antigen-negative embryos when paternal heterozygosity allows.

— Confirm RhIg was administered postpartum within 72 hours.

— Document Rh status in problem list and offer wallet card; advise patient to inform every future provider she is "Rh-negative."

— Educate that every future pregnancy (and every miscarriage, ectopic, procedure, or trauma) requires reassessment for RhIg.

— Sensitized patients should be enrolled in a blood bank registry for future transfusion compatibility (especially with multiple non-D antibodies).

— Consider antigen-matched RBCs for any future transfusion to avoid further alloimmunization.

— Standard postpartum contraception options apply.

— No isoimmunization-specific contraindication, but spacing pregnancies allows time for MFM planning if sensitized.

— Standard postpartum vaccines (Tdap, MMR, varicella if non-immune, influenza) are unaffected.

— RhIg does not interfere with most vaccines but may blunt response to live-attenuated vaccines if given simultaneously; space MMR/varicella by 3 months when feasible.

Step 3 management: At the postpartum visit (4–6 weeks), verify postpartum RhIg was given (for unsensitized) and counsel on lifelong implications. For sensitized patients, schedule a dedicated preconception counseling visit with MFM before any future pregnancy.

For the currently sensitized patient:

For the unsensitized RhD-negative patient (prevention is everything):

Blood bank coordination:

Contraception counseling at discharge:

Vaccinations:

Follow-Up, Monitoring, and Counseling

— First visit: type and screen, ABO/RhD, antibody panel.

— 28 weeks: repeat antibody screen → if negative, administer 300 µg RhIg.

— After any sensitizing event: assess and re-dose.

— Delivery: cord blood typing → postpartum RhIg within 72 h if neonate RhD-positive.

— Titers monthly until 24 weeks, then every 2 weeks.

— Fetal antigen status determination (cffDNA preferred).

— Establish MFM relationship early.

— MCA-PSV every 1–2 weeks starting at 18 weeks until 35 weeks.

— Growth ultrasounds every 3–4 weeks.

— Antenatal testing (NST/BPP) twice weekly from 32 weeks (earlier if IUT-requiring).

— Transcutaneous and serum bilirubin every 4–6 hours initially.

— Hemoglobin and reticulocyte count weekly for 4–6 weeks, then every 2 weeks until 12 weeks—late anemia is common after IUT.

— Neurodevelopmental screening at well-child visits; newborn hearing screen is mandatory and may need repeat in infancy.

— Iron and folate supplementation as needed during recovery.

— Some infants benefit from recombinant erythropoietin for prolonged anemia.

— Explain the difference between "Rh-negative" and "sensitized"—patients often conflate them.

— Emphasize lifelong importance of disclosing Rh status; carry written documentation.

— Discuss reproductive options, recurrence risk, and the need for early prenatal care in any future pregnancy.

— Acknowledge psychological impact of pregnancy loss, hydrops, or prolonged NICU course; offer mental health resources.

Board pearl: Late hyporegenerative anemia (weeks 3–8 of life) is under-recognized. Outpatient pediatricians must continue serial CBCs and reticulocyte counts even after the bilirubin has normalized.

Antepartum monitoring schedule (unsensitized RhD-negative):

Antepartum monitoring (sensitized, below critical titer):

Antepartum monitoring (sensitized, critical titer or anti-Kell, antigen-positive fetus):

Neonatal monitoring after HDFN:

Counseling elements:

Ethical, Legal, and Patient Safety Considerations

— RhIg is a pooled human plasma–derived product; consent should include theoretical (essentially nil with modern viral inactivation) risk of viral transmission.

— Some patients (e.g., Jehovah's Witnesses) decline blood-derived products; document the discussion, alternatives offered, and decision. Acceptance varies—many accept immunoglobulin fractions. Respect autonomy while ensuring the patient understands consequences for future pregnancies.

— Disclose procedure-related fetal loss risk (~1–3% per IUT), preterm labor, infection, and the possibility of emergency cesarean.

— Discuss alternatives (early delivery if gestational age permits) and the consequences of no intervention (likely fetal demise from hydrops).

— Missed postpartum RhIg is one of the most common preventable medical errors in obstetrics. Build into discharge checklist: verify cord blood result, document RhIg given.

— Handoff between OB and pediatrics: communicate antibody status so neonatal team can prepare cross-matched blood and lower phototherapy thresholds.

— Outpatient handoff: ensure pediatrician knows about HDFN to monitor for late anemia.

— Failure to administer RhIg appropriately is a recognized source of malpractice claims when subsequent pregnancies are affected.

— Document every RhIg dose with lot number, route, date, and indication.

— Paternal blood typing requires the partner's informed consent—cannot be performed without his knowledge. If paternity is uncertain or confidential, default to assuming antigen-positive fetus and proceed with cffDNA testing.

— RhIg is inexpensive and effective but underused in low-resource settings—a major contributor to global HDFN burden. In US practice, advocate for coverage and ensure undocumented or uninsured patients receive prophylaxis.

Step 3 management: When a patient refuses RhIg on religious grounds, document the refusal, offer alternative formulations if applicable, ensure she understands implications for future fetuses, and arrange MFM consultation for future pregnancy planning. Continue routine prenatal care without coercion.

Informed consent for RhIg:

Informed consent for IUT and PUBS:

Transition-of-care safety (high-yield Step 3 theme):

Documentation and medical-legal:

Reproductive autonomy and confidentiality:

Equity and access:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: If the question gives you "Rh-negative mother, antibody screen negative, 28 weeks"—give RhIg. If it gives you "Rh-negative mother, antibody screen positive for anti-D, titer 1:32"—do not give RhIg; obtain MCA Doppler and refer to MFM. Pattern-recognize the branch point.

Critical titer for anti-D = 1:16; for anti-Kell = any detectable titer.

300 µg RhIg covers 30 mL fetal whole blood / 15 mL fetal RBCs.

50 µg mini-dose suffices for pregnancy events <12 weeks.

28 weeks + within 72 h postpartum = the two universal RhIg time points.

Kleihauer-Betke quantifies fetomaternal hemorrhage; formula → (% fetal cells × 50)/30 vials, round up + 1.

MCA-PSV >1.5 MoM = moderate-severe fetal anemia → PUBS/IUT.

Anti-Lewis = "Lewis lives, Lewis leaves" (IgM, does not cross placenta, irrelevant in pregnancy).

ABO incompatibility: common mild neonatal jaundice; does not cause fetal hydrops.

Parvovirus B19 = leading infectious cause of non-immune hydrops via aplastic crisis on fetal erythroid precursors.

Mirror (Ballantyne) syndrome: mother's body "mirrors" fetal hydrops with edema and preeclampsia-like features.

Anti-Kell suppresses fetal erythropoiesis—amniotic ΔOD450 underestimates severity; rely on MCA Doppler.

cffDNA from maternal plasma reliably determines fetal RhD after 10–12 weeks.

Weak D maternal phenotype: generally treated as RhD-positive; no RhIg needed (with caveats for partial D).

Passive anti-D after antepartum RhIg can produce titers up to ~1:4 at delivery; do not mistake for sensitization.

Fetal blood for IUT: O-negative, CMV-negative, leukoreduced, irradiated, hematocrit 75–85%, cross-matched to mother.

Neonatal exchange transfusion blood: O-negative cross-matched against maternal serum.

Late hyporegenerative anemia appears at 3–8 weeks of life in IUT survivors—needs serial CBCs.

Kernicterus = bilirubin-induced basal ganglia injury → athetoid CP, sensorineural hearing loss.

Severity worsens with each subsequent affected pregnancy.

Sensitization rate without RhIg ≈ 16%; with RhIg ≈ 0.1–0.3%.

Board Question Stem Patterns

Step 3 management: The single most discriminating question to ask yourself on every Rh question: "Is she sensitized yet?" Antibody screen result decides whether you're in prevention mode (give RhIg) or surveillance mode (MCA Doppler, MFM).

Pattern 1 — Routine prophylaxis: "A 28-year-old G2P1 at 28 weeks, blood type O-negative, antibody screen negative. Next step?" → 300 µg anti-D immune globulin.

Pattern 2 — Postpartum dose: "RhD-negative mother delivers an RhD-positive infant. Cord direct Coombs negative. Next step?" → 300 µg RhIg within 72 hours.

Pattern 3 — First-trimester loss: "RhD-negative woman with spontaneous abortion at 9 weeks. Next step?" → 50 µg RhIg.

Pattern 4 — Trauma: "RhD-negative woman at 26 weeks after MVC. Next step?" → RhIg + Kleihauer-Betke + 4 h fetal monitoring.

Pattern 5 — Already sensitized: "Antibody screen positive for anti-D, titer 1:32, at 20 weeks. Next step?" → MCA-PSV Doppler / refer to MFM (do NOT give RhIg).

Pattern 6 — Anti-Kell: "Antibody screen at 16 weeks reveals anti-Kell, titer 1:4. Next step?" → MCA-PSV at 18 weeks (titer threshold doesn't apply to Kell).

Pattern 7 — MCA Doppler abnormal: "MCA-PSV is 1.7 MoM at 28 weeks." → PUBS with IUT readiness.

Pattern 8 — Father RhD-negative: "Father is RhD-negative confirmed." → No further surveillance needed for Rh isoimmunization.

Pattern 9 — Postpartum titer mistake: "Mother got RhIg at 28 weeks; antibody screen at delivery shows anti-D 1:4." → Passive immunization, not sensitization; give postpartum dose if neonate Rh-positive.

Pattern 10 — Large FMH: "Kleihauer-Betke shows 1.5% fetal cells." → Calculate dose: (1.5 × 50)/30 = 2.5 → round up to 3, add 1 = 4 vials of 300 µg.

Pattern 11 — Non-immune hydrops: "Hydrops on ultrasound; maternal antibody screen negative." → Check parvovirus B19 IgM/PCR, fetal echo, karyotype.

Pattern 12 — ABO vs Rh: "Mother O+, baby A+, jaundice at 24 h, positive direct Coombs, mild." → ABO incompatibility, phototherapy, not Rh-related.

Pattern 13 — Refused RhIg: "Patient declines RhIg for religious reasons." → Document, counsel, respect autonomy, arrange MFM follow-up.

One-Line Recap

Rh isoimmunization is prevented by timely anti-D immune globulin in every RhD-negative unsensitized pregnant patient (28 weeks, postpartum within 72 hours, and after any sensitizing event), and once sensitization has occurred, management pivots to antibody identification, titer monitoring, fetal antigen determination, and MCA-PSV Doppler surveillance with intrauterine transfusion for fetal anemia.

— RhD type and antibody screen on every pregnant patient at the first visit.

— 300 µg RhIg at 28 weeks (after repeat negative screen) and within 72 hours of delivery of an RhD-positive infant.

— 50 µg suffices for events before 12 weeks; standard dose thereafter.

— Re-dose for any sensitizing event: bleeding, trauma, procedure, ECV, miscarriage, ectopic, molar pregnancy.

— Use Kleihauer-Betke to quantify large fetomaternal hemorrhage and calculate additional vials.

— Anti-D critical titer is 1:16; any anti-Kell titer is critical.

— cffDNA non-invasively determines fetal RhD status after 10–12 weeks.

— MCA-PSV >1.5 MoM = moderate-to-severe fetal anemia → PUBS + intrauterine transfusion.

— Deliver uncomplicated sensitized pregnancies at 37–38 weeks; deliver IUT-managed pregnancies at 35–37 weeks after corticosteroids.

— Phototherapy → IVIG → exchange transfusion with O-negative blood cross-matched against maternal serum.

— Monitor for late hyporegenerative anemia for 6–12 weeks.

— Newborn hearing screening and neurodevelopmental follow-up are mandatory.

— Missed postpartum RhIg is a leading preventable obstetric error—build it into discharge checklists.

— Document Rh status and prior RhIg administration in every record; counsel the patient to disclose her Rh-negative status lifelong.

Board pearl: Pattern-match the branch point—antibody screen negative means prevention; antibody screen positive means surveillance. Get that fork right and the rest of the algorithm follows.

Prevention pearls:

Sensitized pregnancy pearls:

Neonatal pearls:

Safety/system pearls: